ORIC anticipates the following upcoming data milestones: ORIC-114: 1H 2025: 2L EGFR exon 20 and 2L+ HER2 exon 20; 2H 2025: 2L+ EGFR atypical; 1H 2026: 1L EGFR exon 20; Mid-2026: 1L EGFR exon 20 combination with SC amivantamab and 1L EGFR atypical. ORIC-944: 4Q 2025 / 1H 2026: Combination with AR inhibitors
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Buy Rating on Oric Pharmaceuticals: Capitalizing on Prostate Cancer Treatment Advances
- Oric recent weakness a buying opportunity, says JPMorgan
- Promising Efficacy and Manageable Safety of ORIC-944 Positions ORIC Shares Favorably
- Positive Outlook for Oric Pharmaceuticals Driven by Promising Trial Results of Mevrometostat and Xtandi Combination
- Oric Pharmaceuticals: Promising Trials and Strong Financials Justify Buy Rating